|Publication number||US8170686 B2|
|Application number||US 11/376,482|
|Publication date||May 1, 2012|
|Filing date||Mar 14, 2006|
|Priority date||Mar 14, 2006|
|Also published as||EP2051656A2, US20070219606, WO2007106520A2, WO2007106520A3|
|Publication number||11376482, 376482, US 8170686 B2, US 8170686B2, US-B2-8170686, US8170686 B2, US8170686B2|
|Inventors||Stephen F. Moreci, Francis P. Grillo, Alfred P. Intoccia, Jr.|
|Original Assignee||Boston Scientific Scimed, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (43), Non-Patent Citations (4), Referenced by (1), Classifications (18), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The invention generally relates to medical devices, methods, and systems for the treatment of urinary incontinence by applying a supportive sling to an anatomical location in a patient. More particularly, in various embodiments, the invention relates to a supportive sling that combines a mechanical sling support with an thermally induced contraction of surrounding tissues.
Stress urinary incontinence (SUI) affects primarily women, but also men, and is generally caused by two conditions, intrinsic sphincter deficiency (ISD) and hypermobility. These conditions may occur independently or in combination. In ISD, the urinary sphincter valve, located within the urethra, fails to close properly (coapt), causing urine to leak out of the urethra during stressful activity. Hypermobility is a condition in which the pelvis floor is distended, weakened or damaged, causing the bladder neck and proximal urethra to rotate and descend in response to increases in intra-abdominal pressure (e.g., due to sneezing, coughing, straining, etc.). As a result, the patient's response time becomes insufficient to promote urethral closure and, consequently, the patient suffers from urine leakage and/or flow.
A popular treatment of SUI uses a surgical sling placed under the bladder neck or the mid-urethra to provide a urethral platform. Placement of the sling limits the endopelvis fascia drop. The sling can be affixed using a bone anchoring method or by an anchorless approach.
Another proposed treatment uses energy delivered to the patients' own pelvic support to selectively contract or shrink at least a portion of the pelvic support tissue, thereby raising the position of the bladder. However, the reported outcome for treatment of urinary incontinence with RF energy alone has indicated statistically disappointing or inconclusive success rates.
Accordingly, there is still a need for an improved approach for supporting the urethra to treat SUI and/or for providing support to other fascia, tendons, and other support tissues which have been strained, or which are otherwise too long to provide the desired support.
The systems and methods described herein are generally directed to the treatment of stress urinary incontinence. More particularly, in various embodiments, the invention provides systems and methods relating to delivering a supportive sling to the periurethral tissue of a patient, wherein the sling is constructed to promote shrinkage of the collagenated tissues proximate to the supportive sling. The present invention relies on delivering energy to the supportive sling to raise the temperature around the pelvic support tissue. At least a section of the supportive sling is electrically conducting, so that this section can be selectively heated. A variety of devices and methods are provided for applying gentle radio-frequency (RF) heating to the conducting sling or sling sections, without significant injury to the support tissues or the surrounding tissue structures.
According to one aspect, a sling assembly for supporting an anatomical location in a patient includes an implantable sling sized and shaped for providing support to tissue at the anatomical location, and an electrically conductive element disposed in or on the implantable sling and couplable to an electromagnetic excitation source.
According to another aspect, a system for applying thermal energy to an anatomical location in a patient includes an implantable sling sized and shaped for providing support to tissue at the anatomical location, an electrically conductive element disposed in or on the sling, and an electromagnetic excitation source coupling energy to the electrically conductive element for conversion into thermal energy.
According to yet another aspect, a method for supporting an anatomical location in a patient includes implanting a sling sized and shaped for providing support to tissue at the anatomical location, coupling an electromagnetic excitation source to an electrically conductive element disposed in or on the sling to produce thermal energy, and heating the tissue proximate to the anatomical location by applying to the tissue the thermal energy produced by the electrically conductive element.
According to yet another aspect, the supportive sling having an electrically conductive element disposed in or on the sling can be used for treatment of urinary incontinence by implanting the sling at an anatomical location of a patient, and coupling an electromagnetic excitation source to the electrically conductive element to produce thermal energy. This heats the tissue proximate to the anatomical location and strengthens or tightens the tissue to provide added support for the urethra.
Shrinking the collagenated tissues around an implanted sling support can also facilitate removal of the sling support from the patient's body after the collagenated tissues has become strong enough to support the pelvic support tissue. According to another aspect, the sling can be removed from an anatomical location in a patient by coupling an electromagnetic excitation source to an electrically conductive element disposed in or on the sling to produce thermal energy and thus heat the tissue proximate to the anatomical location, and externally applying a pulling force to the sling to pull the sling away from the anatomical location.
Embodiments of the invention may include one or more of the following features. The sling may include end terminations, with the electrically conductive element extending between the end terminations of the sling. The electrically conductive element may be applied uniformly along the length of the sling between the end terminations. Alternatively, the electrically conductive element may include low-resistance end portions located proximate to the end terminations, and one or more additional electrically conductive portions with a higher electrical resistance than the end portions, which can be electrically connected to the low-resistance sections. The additional sections may have a reduced thickness compared to the end portions and/or made of a different material than the end portions and/or may be made of a perforated conductive sheet. It will be understood that several of these features may be used in combination.
In this way, more thermal energy can be generated in selected areas. Contact portions may disposed on or near the end terminations for connection to an external source of electric energy, or to an internal, for example, implanted source of electric energy.
In one embodiment, the electrically conductive element may extend over only a portion of the sling, with the sling portion being located at a location of the sling intended for heating and supporting the tissue at the anatomical location. The electrically conductive element may include at least one electrically conductive strand, such as a wire or filament, which may be applied to and/or woven into the sling. The stand may be made of a metal wire, metal-coated plastic, metal-coated insulator, metal-dispersed insulator, semiconductor, and/or a conductive polymer. Alternatively or in addition, the electrically conductive element may include a dispersed electrically conducting material.
In some embodiments, the electrically conductive strands may be substantially non-overlapping, thereby forming individual conductors. In other embodiments, the electrically conductive strands may overlap at predetermined contact points so as to form electrically conducting loops.
Electric energy can be supplied to the electrically conductive portions or elements of the sling either resistively, or can be coupled capacitively or inductively, for example, by using an RF field. The RF field can be applied, for example, with a handheld probe having a probe tip with one or more electrodes or with an RF coil.
Further features and advantages of the invention will be apparent from the following description of illustrative embodiments and from the claims.
The following figures depict certain illustrative embodiments of the invention in which like reference numerals refer to like elements. These depicted embodiments may not be drawn to scale and are to be understood as illustrative of the invention and not as limiting in any way.
In general, the invention is directed to systems, methods and devices for treating urinary incontinence. As described below in more detail, in various illustrative embodiments, the invention provides systems, methods and devices employing thermal treatment of the tissue surrounding an implanted supportive sling by directly producing thermal energy in the sling.
Without limitation, examples of slings, sling assemblies, sling delivery devices and approaches, sling assembly-to-delivery device association mechanisms, and sling anchoring configurations with which the invention may be employed are disclosed in U.S. Pat. No. 6,042,534, entitled “Stabilization Sling for Use in Minimally Invasive Pelvic Surgery,” U.S. Pat. No. 6,755,781, entitled “Medical Slings,” U.S. Pat. No. 6,666,817, entitled “Expandable Surgical Implants and Methods of Using Them,” U.S. Pat. No. 6,042,592, entitled “Thin Soft Tissue Surgical Support Mesh,” U.S. Pat. No. 6,375,662, entitled “Thin Soft Tissue Surgical Support Mesh,” U.S. Pat. No. 6,669,706, entitled “Thin Soft Tissue Surgical Support Mesh,” U.S. Pat. No. 6,752,814, entitled “Devices For Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/918,123, entitled “Surgical Slings,” U.S. patent application Ser. No. 10/641,376, entitled “Spacer for Sling Delivery System,” U.S. patent application Ser. No. 10/641,192, entitled “Medical Slings,” U.S. patent application Ser. No. 10/641,170, entitled “Medical Slings,” U.S. patent application Ser. No. 10/640,838, entitled “Medical Implant,” U.S. patent application Ser. No. 10/460,112, entitled “Medical Slings,” U.S. patent application Ser. No. 10/631,364, entitled “Bioabsorbable Casing for Surgical Sling Assembly,” U.S. patent application Ser. No. 10/092,872, entitled “Medical Slings,” U.S. patent application Ser. No. 10/939,191, entitled “Devices for Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/774,842, entitled “Devices for Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/774,826, entitled “Devices for Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/015,114, entitled “Devices for Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/973,010, entitled “Systems and Methods for Sling Delivery and Placement,” U.S. patent application Ser. No. 10/957,926, entitled “Systems and Methods for Delivering a Medical Implant to an Anatomical Location in a Patient,” U.S. patent application Ser. No. 10/939,191, entitled “Devices for Minimally Invasive Pelvic Surgery,” U.S. patent application Ser. No. 10/918,123, entitled “Surgical Slings,” U.S. patent application Ser. No. 10/832,653, entitled “Systems and Methods for Sling Delivery and Placement,” U.S. patent application Ser. No. 10/642,397, entitled “Systems, Methods and Devices Relating to Delivery of Medical Implants,” U.S. patent application Ser. No. 10/642,395, entitled “Systems, Methods and Devices Relating to Delivery of Medical Implants,” U.S. patent application Ser. No. 10/642,365, entitled “Systems, Methods and Devices Relating to Delivery of Medical Implants,” U.S. patent application Ser. No. 10/641,487, entitled “Systems, Methods and Devices Relating to Delivery of Medical Implants,” U.S. patent application Ser. No. 10/094,352, entitled “System for Implanting an Implant and Method Thereof,” U.S. patent application Ser. No. 10/093,498, entitled “System for Implanting an Implant and Method Thereof,” U.S. patent application Ser. No. 10/093,450, entitled “System for Implanting an Implant and Method Thereof,” U.S. patent application Ser. No. 10/093,424, entitled “System for Implanting an Implant and Method Thereof,” U.S. patent application Ser. No. 10/093,398, entitled “System for Implanting an Implant and Method Thereof,” and U.S. patent application Ser. No. 10/093,371, entitled “System for Implanting an Implant and Method Thereof,” the entire contents of all of which are incorporated herein by reference.
The sling 106 may have a length of about 10 to about 15 cm (about 4-6 inches) and a width of about 1 to about 3 cm, though the length and width of the sling 106 can be adapted to the body part of the patient that requires support. By way of example, in some embodiments, the sling 106 is about 45 cm in length. The sling 106 may be substantially rectangular, as illustrated in
The sling 106 may be fabricated from any of a number of biocompatible materials, such as nylon, polyethylene, polyester, polypropylene, fluoropolymers, copolymers thereof, combinations thereof, or other suitable synthetic material(s). The material may be, for example, a synthetic material that is absorbable by the patient's body. Suitable absorbable synthetic materials can include polyglycolic acid, polylactic acid, and other suitable absorbable synthetic materials. Alternatively, the material for the sling 106 may be derived from mammalian tissue(s) or a combination of mammalian tissue(s) and synthetic material(s). The sling material may be fabricated from one or more yarns, which yarns may be made from one or more materials. The sling 106 may incorporate or be coated with one or more agents to provide a therapeutic effect, for example, to reduce discomfort, to reduce the chance of infection and/or to promote tissue growth.
Depending on the specific design of the sling, the sling can be implanted via an initial transvaginal incision, or sometimes via additional abdominal or ishiopubic incisions. The particular method of implanting the sling is not the subject of the present invention. An exemplary method, such as the method using the aforedescribed end terminations or bone anchors 102 a, 102 b illustrated in
In another illustrative embodiment depicted in
According to various illustrative embodiments, the supportive sling assembly 100 may be made of any suitable biocompatible material. The supportive sling assembly 100 may be made, for example, of a synthetic material such as nylon, polyethylene, polyester, polypropylene, fluoropolymers or a co-polymer thereof. In some illustrative embodiments, they may be formed, at least in part, from a mammalian tissue material such as bovine, porcine, equine, human cadaver or engineered tissue. In some illustrative embodiments, the material of the sling assembly 100 may include a combination of synthetic and mammalian tissue materials. According to another feature, at least a portion of the sling assembly 100 may be biodegradable and may also dissolve and/or be absorbed into the patient's tissues.
According to another feature, the sling assembly 100 may be configured to dissolve within a particular time range. The sling assembly 100 may be configured, for example, to substantially absorb (or have a portion that substantially absorbs) into the patient's tissues within about 2, 4, 6 or 8 or more weeks from the time the sling is implanted. Preferably, the sling assembly 100 remain structurally intact long enough for scar tissue and/or other neighboring cells or tissues to grow into the sling 106 to keep the sling in place.
According to other illustrative embodiments, the sling 106 may be treated with one or more agents for release into the patient's tissues. One illustrative agent promotes, when applied to the patient's tissues in a pharmaceutically acceptable amount, well-organized collagenous tissue growth, such as scar tissue growth, preferably, in large quantities. According to one feature, the agent may or may not block or delay the dissolvability of the sling 106. This may be controlled by selecting differing methods for loading the agent onto the sling 106. The tissue growth factor may include natural and/or recombinant proteins for stimulating a tissue response so that collagenous tissue, such as scar tissue, growth is enhanced. The tissue growth factor may similarly include natural and/or recombinant proteins for stimulating a tissue response so that tissue growth is enhanced. Furthermore, the tissue growth factor may include non-protein, protein, small molecule agents that mimic the effects of a natural and/or recombinant protein on scar or non-scar tissue growth. Exemplary growth factors that may be used include, but are not limited to, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor-beta (TGF-beta), vascular endothelium growth factor (VEGF), Activin/TGF and sex steroid, bone marrow growth factor, growth hormone, Insulin-like growth factor 1, and combinations thereof. Exemplary small molecule growth factors include, but are not limited to, small molecule agents that mimic the effects of one or more of the foregoing growth factors. The agent may also include a hormone, including but not limited to estrogen, steroid hormones, and other hormones to promote growth of appropriate collagenous tissue such as scar tissue. The agent may also include stem cells or other suitable cells derived from the host patient or derived from a suitable donor. Suitable cells include, without limitation, embryonic stem cells, adult stem cells, and other suitable non-stem cells. Stem or non-stem cells may be fibroblastic, mesenchymal, myoblastic, endothelial, and other cell types capable of maturing into appropriate tissues.
In various illustrative embodiments, the agent may include one or more therapeutic agents. The therapeutic agents may be, for example, anti-inflammatory agents, including steroidal and non-steroidal anti-inflammatory agents, analgesic agents, including narcotic and non-narcotic analgesics, local anesthetic agents, antispasmodic agents, growth factors, gene-based therapeutic agents, and combinations thereof. Such therapeutic agents include protein and non-protein, small molecule agents.
According to another illustrative embodiment, the sling 106 may be treated with one or more inflammatory agents for release into the patient's tissues. Inflammatory agents may include, for example, oleoresin capsicum, orthochlorobenzalonoitrate, prostaglandins, antiprogesterone, relaxin, histamines, glucocorticoids, leukotrienes, thromboxanes, C5a, TNF-alpha, NF-Kappa-B, GM-CSF, interleukins, IL-18, IL-8, IL-6, IL-1β, IL-1 alpha, iNOS, TGFβ, Resistin, pro-inflammatory cytokines, agonists or promoters of pro-inflammatory cytokines, bacterial lipopolysaccharide (LPS), phorbol ester, TPA, NO, superoxide, macrophage colony-stimulating factor, cyclophilins, chemokines, eicosanoids, COX-1, COX-2, PLA2, bi- and tri-specific antibodies. When applied to the patient's tissues in a pharmaceutically acceptable amount, inflammatory agents stimulate the rate of tissue in-growth to ensure that the sling is anchored rapidly in the surrounding tissue, while maintaining the sling tension applied at the time of surgical placement of the sling. The inflammatory response can thus enhance the thermal effects produced by heating the tissue.
The RF energy can be applied to the tissue with probes which are moved by the practitioner across the area to be treated. Bipolar electric current is resistively coupled into the tissue through an electrode either in a single electrode configuration (where a ground plate is attached to the patient) or a dual electrode configuration (where the current flows between two electrodes). The temperature of the target tissue structure can be raised to a value in the range from 70° C. to 95° C., for a time sufficient to effect the desired tissue shrinkage, for example, from 1 minute to 2 minutes. The total amount of energy delivered will depend in part on which tissue structure is being treated as well as the specific temperature and time selected for the protocol. The power delivered will often be in the range from 2 W to 5 W. However, according to several medical reports, the benefits obtained by treating urinary incontinence, and also fecal incontinence, with RF energy alone were found to be statistically inconclusive.
Moreover, delivery of RF energy to tissue is difficult due to the low RF conductivity of tissue. Direct tissue heating by RF is a function of many parameters, including the mass, thermal conductivity, and heat capacity of the body part under study; its level of blood perfusion; ambient temperature; air circulation; the specific pulse sequence; and RF frequency. The FDA has used the tissue RF specific absorption rate (SAR) as the parameter of heating to establish guidelines for allowable RF energy deposition. The SAR is expressed in units of watts per kilogram of body weight (W/kg). The general guideline used by the FDA to establish allowable RF energy deposition is based on levels that produce a maximum change in tissue temperature of 1° C. According to the specific FDA criteria for SAR limits, the SAR must be no greater than (a) 4 W/kg averaged over whole body for any 15-minute period, (b) 3 W/kg averaged over the head for any 10-minute period, or (c) 8 W/kg in any gram of tissue in the head or torso or 12 W/kg in any gram of tissue in the extremities for any period of 5 minutes.
As mentioned above, attempts have been made to treat urinary incontinence without a supportive sling by transvaginally applying a RF signal directly to the endopelvic fascia to selectively shrink fascia and other collagenated tissue. Tissue contraction results from controlled heating of the tissue by affecting the collagen molecules of the tissue. Contraction may occur as a result of heat-induced uncoiling as the collagen β-pleated structure and subsequent re-entwinement as the collagen returns to body temperature.
According to the illustrative embodiment, electric energy, such as RF energy, may be applied to an electrically conducting material or structure disposed on or in the sling 106. The RF energy then can be selectively coupled to the conducting material to controllable heat the conducting material, to transfer thermal energy to the tissue near and/or surrounding the conducting material or structure.
As illustrated in
According to another illustrative embodiment depicted in
In an alternative illustrative embodiment shown in
According to one illustrative embodiment, the electrical conductors described above can be implemented as electrically conducting fibers, for example, fibers made of a conductive polymer, such as conductive polymer strands commercially available from Santa Fe Science and Technology, Santa Fe, N.Mex., USA and sold under the name Panion™. Other conductive polymers, such as tetrathiafulvalene-tetracyanoquinodimethane (TTF-TCNQ), may also be used. The conductive polymer can be woven into the existing sling geometry and should be biocompatible, but may also be biodegradable. More generally, the employed conductive polymer may have a biocompatibility similar to that of the sling material.
According to one advantage of the invention, inductive coupling does not require direct contact with the sling 206 or its components, so RF power can be transferred to the heated zone of sling 206 without disturbing the surrounding tissue. Moreover, RF energy can be inductively coupled to any conductive component or structure regardless of its shape or physical dimension, which may only affect the coupling efficiency.
Turning now to
According to another illustrative embodiment, the sling 206, or at least a heated section of the sling 206, may include a therapeutic agent for lifting or otherwise modifying the muscle tissue supporting the bladder and/or urethra. The therapeutic agent may also include drugs that enhance the therapeutic effect of the sling 206.
According to a further illustrative embodiment, energy may be applied to the sling 206 for the purpose of dissolving or removing the sling material after implantation. This concept was tested by implanting conductive esophageal stents in pigs, where the stents remained for >7 days to allow tissue ingrowth. Esophageal stents are typically made either from Nitinol™ metal, which is a titanium-nickel alloy, or stainless steel. When RF power was subsequently applied to the stents, the stents could be removed by pulling with minimal applied force.
As shown in
Alternatively, the temperature of the sling material can be measured, for example, with an embedded electric probe, such as a thermocouple or thermistor, or an optical probe. Alternatively, the temperature-dependent properties of the conductive material itself, such as the aforedescribed Panion™ polymer material, may be used for temperature measurements. According to one illustrative embodiment, to promote collagen shrinking and prevent irreversible cell damage (necrosis), heating of the surrounding tissue is limited to temperatures between about 60° C. and about 90° C., and in one implementation to between about 60° C. and 80° C.
As mentioned before, a probe 40 with a single electrode, such as electrode 48, may be used for supplying RF energy. As mentioned above, the counter-electrode may be implemented as a large-area ground plate attached external to the patient's body.
For inductively coupling the RF energy, for example, to the loop depicted in
To aid spreading of the generated heat across the sling or portions of the sling, the material of the sling may also be thermally conductive. The thermal conductivity of the sling material may be enhanced by embedding in the sling materials that are capable of increasing the thermal conductivity of the sling. Such materials could be metals and/or ceramics and are preferably biocompatible.
In another illustrative embodiment depicted in
The energized centering tab 107 of
In another exemplary configuration, the temperature of the sling 106 and surrounding tissue is raised via the delivery devices that are used to insert the end terminations 102 a and 102 b through the obturator foramen 114 and 112. More particularly, such delivery devices may be configured to deliver electric or thermal energy directly to the sling 106 when inserting the end terminations 102 a and 102 b into the foramen 804 and 802.
While the invention has been disclosed in connection with the illustrative embodiments shown and described in detail, various modifications and improvements may be made thereto without departing from the spirit and scope of the invention. By way of example, although the illustrative embodiments have been described in conjunction with a supportive sling for treating urinary incontinence, other applications can be contemplated. For example, the electrically energized support structure of the invention may be used to treat male incontinence, hernias, and other ailments where muscle tissue which has slackened for a variety of reasons needs to be strengthened or tightened. Accordingly, the spirit and scope of the invention is to be limited only by the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3705575 *||Sep 22, 1970||Dec 12, 1972||Lynn Euryl Edwards||Incontinence device for female use|
|US5733337||Apr 7, 1995||Mar 31, 1998||Organogenesis, Inc.||Tissue repair fabric|
|US6042534||Feb 13, 1998||Mar 28, 2000||Scimed Life Systems, Inc.||Stabilization sling for use in minimally invasive pelvic surgery|
|US6042592||Aug 4, 1997||Mar 28, 2000||Meadox Medicals, Inc.||Thin soft tissue support mesh|
|US6091995 *||Aug 13, 1997||Jul 18, 2000||Surx, Inc.||Devices, methods, and systems for shrinking tissues|
|US6127597||Mar 6, 1998||Oct 3, 2000||Discotech N.V.||Systems for percutaneous bone and spinal stabilization, fixation and repair|
|US6216704 *||Aug 12, 1998||Apr 17, 2001||Surx, Inc.||Noninvasive devices, methods, and systems for shrinking of tissues|
|US6354991||Oct 6, 1999||Mar 12, 2002||Bio Control Medical Ltd||Incontinence treatment device|
|US6375662||Nov 23, 1999||Apr 23, 2002||Scimed Life Systems, Inc.||Thin soft tissue surgical support mesh|
|US6418930 *||Nov 14, 2000||Jul 16, 2002||Mayo Foundation For Medical Education And Research||Anatomic incontinence pessary|
|US6463331||Mar 30, 2000||Oct 8, 2002||Novasys Medical, Inc.||Application of energy and substances in the treatment of uro-genital disorders|
|US6470219||Oct 2, 2000||Oct 22, 2002||Novasys Medical, Inc.||Apparatus and method for treating female urinary incontinence|
|US6652449||Oct 5, 1999||Nov 25, 2003||Bio Control Medical, Ltd.||Control of urge incontinence|
|US6666817||Oct 5, 2001||Dec 23, 2003||Scimed Life Systems, Inc.||Expandable surgical implants and methods of using them|
|US6669706||Dec 18, 2001||Dec 30, 2003||Scimed Life Systems, Inc.||Thin soft tissue surgical support mesh|
|US6752814||Nov 12, 2001||Jun 22, 2004||Scimed Life Systems, Inc.||Devices for minimally invasive pelvic surgery|
|US6755781||Jul 27, 2001||Jun 29, 2004||Scimed Life Systems, Inc.||Medical slings|
|US6840954||Dec 20, 2001||Jan 11, 2005||Solarant Medical, Inc.||Systems and methods using vasoconstriction for improved thermal treatment of tissues|
|US6991597 *||Mar 7, 2002||Jan 31, 2006||Boston Scientific Scimed, Inc.||System for implanting an implant and method thereof|
|US7070558||Jun 12, 2003||Jul 4, 2006||Boston Scientific Scimed, Inc.||Medical slings|
|US20010003798||Jul 10, 1998||Jun 14, 2001||Phyllis K. Kristal||Balloon catheter for intra-urethral radio-frequency urethral enlargement|
|US20010020162||May 8, 2001||Sep 6, 2001||Brian Mosel||Urinary incontinence diagnostic system|
|US20020049425||Oct 6, 1999||Apr 25, 2002||Brian J. Mosel||Urinary incontinence diagnostic system|
|US20020062060||Jan 15, 2002||May 23, 2002||Yossi Gross||Incontinence treatment device|
|US20030009201 *||Jun 29, 2001||Jan 9, 2003||Peter Forsell||Urinary dysfunction treatment apparatus|
|US20030028180||Aug 1, 2001||Feb 6, 2003||Nicholas Franco||Apparatus and method for treating urinary stress incontinence|
|US20030144575 *||Feb 8, 2001||Jul 31, 2003||Peter Forsell||Urinary incontinence treatment apparatus|
|US20040073234||Aug 14, 2003||Apr 15, 2004||Chu Michael S.H.||Medical implant|
|US20040116944||Aug 14, 2003||Jun 17, 2004||Scimed Life Systems, Inc.||Spacer for sling delivery system|
|US20050038451||Aug 14, 2003||Feb 17, 2005||Scimed Life Systems, Inc.||Medical slings|
|US20050038452||Aug 14, 2003||Feb 17, 2005||Scimed Life Systems, Inc.||Medical slings|
|US20050096499||Aug 13, 2004||May 5, 2005||Scimed Life Systems, Inc||Surgical slings|
|US20070123746 *||Nov 16, 2005||May 31, 2007||Boston Scientific Scimed, Inc.||Devices for minimally invasive pelvic surgery|
|US20070185541 *||Aug 2, 2006||Aug 9, 2007||Diubaldi Anthony||Conductive mesh for neurostimulation|
|US20070260288 *||May 5, 2006||Nov 8, 2007||Yossi Gross||Apparatus for treating stress and urge incontinence|
|US20080009914 *||Jul 10, 2007||Jan 10, 2008||Ams Research Corporation||Systems and Methods for Implanting Tissue Stimulation Electrodes in the Pelvic Region|
|US20090043356 *||Feb 22, 2007||Feb 12, 2009||Ams Research Corporation||Electrode Sling for Treating Stress and Urge Incontinence|
|US20090259092 *||May 18, 2009||Oct 15, 2009||Ogdahl Jason W||Adjustable Sling and Method of Treating Pelvic Conditions|
|US20100049289 *||Sep 11, 2009||Feb 25, 2010||Ams Research Corporation||Tissue anchor|
|US20100217340 *||Aug 26, 2010||Ams Research Corporation||Implantable Medical Device Connector System|
|WO1998019613A1||Nov 5, 1997||May 14, 1998||Surx Inc||Devices, methods and systems for shrinking tissues|
|WO2003105727A1||Jun 12, 2003||Dec 24, 2003||Scimed Life Systems, Inc.||Medical slings|
|WO2004112656A2||Jun 14, 2004||Dec 29, 2004||Trivascular Inc||Inflatable implant|
|1||Deurloo et al., "Application of a capacitive-coupling interstitial hyperthermia system at 27 MHz: study of difference applicator configurations," Phy Med. Biol, 36(1):119-132, (1991).|
|2||Korni et al., "Outcome of Trans-Vaginal Radio Frequency for Treatment of Women with Stress Urinary Incontinence," University of Rochester Medical Center, p. 343.|
|3||Surgery Section-Transanal Radiofrequency Treatment of Fecal Incontinence, The Regence Group, 3 pages, (2003).|
|4||Surgery Section—Transanal Radiofrequency Treatment of Fecal Incontinence, The Regence Group, 3 pages, (2003).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US20130204078 *||Feb 7, 2013||Aug 8, 2013||Boston Scientific Scimed, Inc.||Porous surgical films|
|U.S. Classification||607/101, 600/29, 607/138, 600/37, 600/30|
|International Classification||A61F2/02, A61F2/04, A61F7/00|
|Cooperative Classification||A61B2018/00791, A61B2018/1407, A61F2250/0045, A61F2250/0001, A61B18/1492, A61F2/0045, A61B2018/00642, A61B2018/00702|
|European Classification||A61F2/00B6B4, A61B18/14V|
|Mar 14, 2006||AS||Assignment|
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORECI, STEPHEN F.;GRILLO, FRANCIS P.;INTOCCIA JR., ALFRED P.;REEL/FRAME:017648/0391;SIGNING DATES FROM 20051219 TO 20060302
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORECI, STEPHEN F.;GRILLO, FRANCIS P.;INTOCCIA JR., ALFRED P.;SIGNING DATES FROM 20051219 TO 20060302;REEL/FRAME:017648/0391
|Oct 14, 2015||FPAY||Fee payment|
Year of fee payment: 4